Philogen SpA

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

10 Jun 2025 14:55:14 By Nasdaq GlobeNewswire

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

19 Feb 2024 22:30:00 By Nasdaq GlobeNewswire

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

04 Dec 2023 23:30:00 By Nasdaq GlobeNewswire

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

04 Dec 2023 00:00:00 By Nasdaq GlobeNewswire

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

16 Oct 2023 05:21:36 By Nasdaq GlobeNewswire

Philogen Announces Clinical Trial Collaboration with MSD

31 May 2023 23:30:00 By Nasdaq GlobeNewswire

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

29 May 2023 22:00:00 By Nasdaq GlobeNewswire

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

24 May 2023 23:00:00 By Nasdaq GlobeNewswire

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

27 Mar 2023 23:00:00 By Nasdaq GlobeNewswire

Philogen Provides Corporate Update

30 Nov 2022 23:00:00 By Nasdaq GlobeNewswire

Philogen Provides Corporate Update

23 Jun 2022 00:00:00 By Nasdaq GlobeNewswire

Philochem and Bracco Imaging Announce a Collaboration on the Development of a Small Molecule for Diagnostic or Medical Imaging Applications

22 Mar 2022 00:05:00 By Nasdaq GlobeNewswire

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

06 Jan 2022 23:00:00 By Nasdaq GlobeNewswire

PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS

24 Nov 2021 00:00:00 By Nasdaq GlobeNewswire

Philogen Provides Corporate Update

11 Nov 2021 23:00:00 By Nasdaq GlobeNewswire

Philogen Provides Corporate Update

29 Sep 2021 01:58:35 By Nasdaq GlobeNewswire

Philogen Announces R&D Program Update

01 Jul 2021 23:00:00 By Nasdaq GlobeNewswire

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

12 May 2021 10:00:00 By Nasdaq GlobeNewswire